Allakos Inc. ($ALLK) is set to be acquired by Concentra Biosciences, LLC, in a definitive merger agreement that values the company at $0.33 per share in cash. The acquisition is part of a tender offer scheduled to launch by April 15, 2025. Following the announcement, Allakos shares surged by approximately 46%. This acquisition is seen as a potential lifeline for the company amid ongoing challenges in the biotech sector. In related market activity, other biotech stocks such as QNRX and SBFM also reported significant gains, with QNRX rising by 90% after announcing positive clinical data, and SBFM increasing by 50% following the results of its mRNA cancer therapy.